BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60:643-653. [PMID: 24076364 DOI: 10.1016/j.jhep.2013.09.016] [Cited by in Crossref: 83] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Chou AH, Lin YS, Wu VC, Chen FT, Yang CH, Chen DY, Chen SW. Effect of medications after cardiac surgery on long-term outcomes in patients with cirrhosis. Medicine (Baltimore) 2021;100:e23075. [PMID: 33592816 DOI: 10.1097/MD.0000000000023075] [Reference Citation Analysis]
2 Ngwa T, Orman E, Gomez EV, Vuppalanchi R, Kubal C, Chalasani N, Ghabril M. Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation. BMC Gastroenterol 2020;20:4. [PMID: 31906860 DOI: 10.1186/s12876-019-1155-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Lindsay AJ, Burton J, Ray CE. Paracentesis-Induced Circulatory Dysfunction: A Primer for the Interventional Radiologist. Semin Intervent Rad. 2014;31:276-278. [PMID: 25177092 DOI: 10.1055/s-0034-1382799] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
4 Kirnake V, Arora A, Gupta V, Sharma P, Singla V, Bansal N, Goyal M, Chawlani R, Kumar A. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study. J Clin Exp Hepatol 2016;6:175-85. [PMID: 27746613 DOI: 10.1016/j.jceh.2016.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
5 Khan RS, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65:1208-1223. [PMID: 26997540 DOI: 10.1016/j.metabol.2016.02.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
6 Chen Y, Li X. Can red blood cell distribution width predict the severity and prognosis of hepatitis B virus-related diseases? Dig Liver Dis 2020;52:1372. [PMID: 32893172 DOI: 10.1016/j.dld.2020.07.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Møller S, Bendtsen F. Cirrhotic Multiorgan Syndrome. Dig Dis Sci 2015;60:3209-25. [DOI: 10.1007/s10620-015-3752-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
8 Lopez-Lopez V, Gomez Ruiz A, Lopez-Conesa A, Brusadin R, Cayuela V, Caballero-Illanes A, Torres M, Robles Campos R. Effects of primary hypertension treatment in the oncological outcomes of hepatocellular carcinoma. Ann Transl Med 2020;8:844. [PMID: 32793688 DOI: 10.21037/atm.2020.04.40] [Reference Citation Analysis]
9 Nair H, Berzigotti A, Bosch J. Emerging therapies for portal hypertension in cirrhosis. Expert Opin Emerg Drugs 2016;21:167-81. [PMID: 27148904 DOI: 10.1080/14728214.2016.1184647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ge PS, Runyon BA. When Should the β-Blocker Window in Cirrhosis Close? Gastroenterology 2014;146:1597-9. [DOI: 10.1053/j.gastro.2014.04.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
11 Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken). 2018;11:141-144. [PMID: 30992805 DOI: 10.1002/cld.714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Ge PS, Runyon BA. Beta-blockers in cirrhosis: Thank you for your attention. Journal of Hepatology 2014;61:451-2. [DOI: 10.1016/j.jhep.2014.04.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
13 Harding DJ, Perera MTP, Chen F, Olliff S, Tripathi D. Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol 2015; 21(22): 6769-6784 [PMID: 26078553 DOI: 10.3748/wjg.v21.i22.6769] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
14 Møller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int 2014;34:1153-63. [DOI: 10.1111/liv.12549] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
15 Lachlan NJ, Fallowfield JA. Editorial: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther 2015;41:1297. [PMID: 25968148 DOI: 10.1111/apt.13206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
16 Porcel JM. Management of refractory hepatic hydrothorax. Curr Opin Pulm Med 2014;20:352-7. [PMID: 24811830 DOI: 10.1097/MCP.0000000000000058] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
17 Günay N, Erdem Ş, Güvenç TS, Bulur A, Özdil K, Hasdemir H, Uyan C. Morphologic and Functional Changes in Right‐Sided Cardiac Chambers in Patients With Chronic Liver Disease and Normal Pulmonary Artery Pressure. J Ultrasound Med 2018;37:1681-91. [DOI: 10.1002/jum.14516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wu VC, Chen SW, Ting PC, Chang CH, Wu M, Lin MS, Hsieh MJ, Wang CY, Chang SH, Hung KC, Hsieh IC, Chu PH, Wu CS, Lin YS. Selection of β-Blocker in Patients With Cirrhosis and Acute Myocardial Infarction: A 13-Year Nationwide Population-Based Study in Asia. J Am Heart Assoc 2018;7:e008982. [PMID: 30371327 DOI: 10.1161/JAHA.118.008982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ferrarese A, Tikhonoff V, Casiglia E, Angeli P, Fasolato S, Faggian D, Zanetto A, Germani G, Russo FP, Burra P, Senzolo M. Hemodynamic Evaluation of Nonselective β-Blockers in Patients with Cirrhosis and Refractory Ascites. Gastroenterol Res Pract 2018;2018:4098210. [PMID: 29861720 DOI: 10.1155/2018/4098210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Sharma S, Stine JG, Verbeek T, Bezinover D. Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00601-7. [PMID: 34391652 DOI: 10.1053/j.jvca.2021.07.020] [Reference Citation Analysis]
21 Sersté T, Njimi H, Degré D, Deltenre P, Schreiber J, Lepida A, Trépo E, Gustot T, Moreno C. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis. Liver Int. 2015;35:1974-1982. [PMID: 25611961 DOI: 10.1111/liv.12786] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
22 Facciorusso A, Antonino M, Orsitto E, Sacco R. Primary and secondary prophylaxis of spontaneous bacterial peritonitis: current state of the art. Expert Rev Gastroenterol Hepatol 2019;13:751-9. [PMID: 31304804 DOI: 10.1080/17474124.2019.1644167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Role of band ligation for secondary prophylaxis of variceal bleeding. World J Gastroenterol 2018; 24(26): 2902-2914 [PMID: 30018485 DOI: 10.3748/wjg.v24.i26.2902] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Rajakumar A, Kaliamoorthy I, Rela M, Mandell MS. Small-for-Size Syndrome: Bridging the Gap Between Liver Transplantation and Graft Recovery. Semin Cardiothorac Vasc Anesth 2017;21:252-61. [DOI: 10.1177/1089253217699888] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Toshikuni N, Takuma Y, Tsutsumi M. Management of gastroesophageal varices in cirrhotic patients: current status and future directions. Ann Hepatol 2016;15:314-25. [PMID: 27049485 DOI: 10.5604/16652681.1198800] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
26 Fu H, Sun K, Li J, Gong W, Agopian V, Yan M, Busuttil RW, Steadman RH, Xia VW. Preoperative beta blockade and severe intraoperative bradycardia in liver transplantation. Clin Transplant 2018;32:e13422. [DOI: 10.1111/ctr.13422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Rajoriya N, Tripathi D. Non-selective beta-blockers in cirrhosis: Current concepts and controversies. World J Pharmacol 2016; 5(1): 15-31 [DOI: 10.5497/wjp.v5.i1.15] [Reference Citation Analysis]
28 Kimer N, Feineis M, Møller S, Bendtsen F. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol. 2015;50:129-137. [PMID: 25113796 DOI: 10.3109/00365521.2014.948053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
29 Schwartz G, Darling JO, Mindo M, Damicis L. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. Target Oncol 2020;15:549-65. [PMID: 32770441 DOI: 10.1007/s11523-020-00736-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
30 Stanley AJ, Dickson S, Hayes PC, Forrest EH, Mills PR, Tripathi D, Leithead JA, MacBeth K, Smith L, Gaya DR, Suzuki H, Young D. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol. 2014;61:1014-1019. [PMID: 24953021 DOI: 10.1016/j.jhep.2014.06.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
31 Tapper EB, Bonder A, Cardenas A. Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review. The American Journal of Medicine 2016;129:461-7. [DOI: 10.1016/j.amjmed.2015.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
32 Vorobioff JD, Groszmann RJ. Prevention of portal hypertension: from variceal development to clinical decompensation. Hepatology. 2015;61:375-381. [PMID: 24913395 DOI: 10.1002/hep.27249] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
33 Ferrarese A, Tsochatzis E, Burroughs AK, Senzolo M. Beta-blockers in cirrhosis: therapeutic window or an aspirin for all? J Hepatol. 2014;61:449-450. [PMID: 24768827 DOI: 10.1016/j.jhep.2014.03.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
34 Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem 2021;:114388. [PMID: 34587512 DOI: 10.1016/j.ab.2021.114388] [Reference Citation Analysis]
35 Facciorusso A, Roy S, Livadas S, Fevrier-paul A, Wekesa C, Kilic ID, Chaurasia AK, Sadeq M, Muscatiello N. Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites. Dig Dis Sci 2018;63:1737-46. [DOI: 10.1007/s10620-018-5092-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
36 Peeraphatdit TB, Kamath PS, Shah VH. Beta-blockers in patients with advanced cirrhosis: Red light, green light, yellow light…. Liver Transpl 2017;23:725-6. [PMID: 28452116 DOI: 10.1002/lt.24780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
37 Lee SK, Song MJ, Kim SH, Ahn HJ. Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis. Clin Mol Hepatol. 2018;24:409-416. [PMID: 30145855 DOI: 10.3350/cmh.2018.0034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
38 Talmaciu MM, Bodoki E, Oprean R. Global chemical reactivity parameters for several chiral beta-blockers from the Density Functional Theory viewpoint. Clujul Med 2016;89:513-8. [PMID: 27857521 DOI: 10.15386/cjmed-610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Nevens F, Bittencourt PL, Coenraad MJ, Ding H, Hou MC, Laterre PF, Mendizabal M, Ortiz-Olvera NX, Vorobioff JD, Zhang W, Angeli P. Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Dig Dis Sci 2019;64:1419-31. [PMID: 30684079 DOI: 10.1007/s10620-018-5448-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Abukhalaf AA, Alomar AA, Alsalame NM, Sumaya OY, Alessa OM, Alasbali MM, Alaska YA. Inappropriate use of beta-blockers among medical and dental students at King Saud University, Riyadh. J Family Med Prim Care 2020;9:4391-5. [PMID: 33110866 DOI: 10.4103/jfmpc.jfmpc_696_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol 2020; 26(40): 6111-6140 [PMID: 33177789 DOI: 10.3748/wjg.v26.i40.6111] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Wong RJ, Robinson A, Ginzberg D, Gomes C, Liu B, Bhuket T. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis. Liver Int 2019;39:1080-8. [PMID: 30614656 DOI: 10.1111/liv.14040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
43 Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. World J Gastroenterol 2018; 24(38): 4356-4368 [PMID: 30344420 DOI: 10.3748/wjg.v24.i38.4356] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
44 Arab JP, Barrera F, Arrese M. Bile Acids and Portal Hypertension. Ann Hepatol 2017;16:s83-6. [PMID: 29080345 DOI: 10.5604/01.3001.0010.5500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Prins KW, Thenappan T, Weir EK, Kalra R, Pritzker M, Archer SL. Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. J Am Heart Assoc 2019;8:e011343. [PMID: 30590974 DOI: 10.1161/JAHA.118.011343] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
46 Bloom S, Kemp W, Lubel J. Portal hypertension: pathophysiology, diagnosis and management: Portal hypertension current concepts. Intern Med J 2015;45:16-26. [DOI: 10.1111/imj.12590] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
47 Kuo SZ, Lizaola B, Hayssen H, Lai JC. Beta-blockers and physical frailty in patients with end-stage liver disease. World J Gastroenterol 2018; 24(33): 3770-3775 [PMID: 30197482 DOI: 10.3748/wjg.v24.i33.3770] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Hsu WF, Yu SH, Lin JT, Wu JC, Hou MC, Huang YH, Wu CY, Peng CY. Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study. Gastroenterol Res Pract 2019;2019:1743290. [PMID: 31687012 DOI: 10.1155/2019/1743290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Garbuzenko DV. [Aspects of pathogenetc pharmacotherapy for portal hypertension in liver cirrhosis]. Ter Arkh. 2016;88:101-108. [PMID: 27135108 DOI: 10.17116/terarkh2016888101-108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
50 Kim SG, Larson JJ, Lee JS, Therneau TM, Kim WR. Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl. 2017;23:733-740. [PMID: 28187503 DOI: 10.1002/lt.24744] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
51 Caldeira D, Rodrigues FB, Duarte MM, Sterrantino C, Barra M, Gonçalves N, Pinto FJ, Ferreira JJ, Costa J. Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis. Drug Saf 2018;41:77-86. [PMID: 28786035 DOI: 10.1007/s40264-017-0586-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
52 Lesmana CRA, Raharjo M, Gani RA. Managing liver cirrhotic complications: Overview of esophageal and gastric varices. Clin Mol Hepatol 2020;26:444-60. [PMID: 33053928 DOI: 10.3350/cmh.2020.0022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
53 Cifuentes LI, Gattini D, Torres-Robles R, Gana JC. Beta-blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. Cochrane Database Syst Rev 2021;1:CD011973. [PMID: 33498095 DOI: 10.1002/14651858.CD011973.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
54 Gana JC, Cifuentes LI, Gattini D, Villarroel Del Pino LA, Peña A, Torres-Robles R. Band ligation versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis. Cochrane Database Syst Rev 2019;9:CD010546. [PMID: 31550050 DOI: 10.1002/14651858.CD010546.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
55 Facciorusso A. Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects.Ther Clin Risk Manag. 2019;15:1383-1391. [PMID: 31819465 DOI: 10.2147/TCRM.S205328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
57 Garbuzenko DV. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis. World J Gastroenterol 2015; 21(20): 6117-6126 [PMID: 26034348 DOI: 10.3748/wjg.v21.i20.6117] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
58 Rajapaksha IG, Gunarathne LS, Angus PW, Herath CB. Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options. J Clin Med 2021;10:702. [PMID: 33670126 DOI: 10.3390/jcm10040702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41:1116-1131. [PMID: 25819304 DOI: 10.1111/apt.13172] [Cited by in Crossref: 83] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
60 Thalheimer U, Bosch J, Burroughs AK. An apology for beta blockers. J Hepatol 2014;61:450-1. [PMID: 24768757 DOI: 10.1016/j.jhep.2014.03.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
61 Nuthalapati A, Schluterman N, Khanna A, Greenberg D, Thuluvath PJ. Impact of Acute Kidney Injury on Mortality of Patients Hospitalized for Complications of Cirrhosis. J Clin Exp Hepatol 2017;7:290-9. [PMID: 29234192 DOI: 10.1016/j.jceh.2017.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, Blacky A, Ferlitsch A, Sieghart W. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680-1690.e1. [PMID: 24631577 DOI: 10.1053/j.gastro.2014.03.005] [Cited by in Crossref: 245] [Cited by in F6Publishing: 179] [Article Influence: 35.0] [Reference Citation Analysis]
63 Kalambokis GN, Christodoulou D, Baltayiannis G, Christou L. Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites. Hepatology 2016;64:1806-8. [PMID: 27016449 DOI: 10.1002/hep.28575] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
64 Mozos I. Arrhythmia risk in liver cirrhosis. World J Hepatol 2015; 7(4): 662-672 [PMID: 25866603 DOI: 10.4254/wjh.v7.i4.662] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
65 Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med 2020;8:220-36. [PMID: 33511049 DOI: 10.2478/jtim-2020-0035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Thomson MJ, Lok AS, Tapper EB. Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes. Liver Int 2018;38:1882-90. [PMID: 29845749 DOI: 10.1111/liv.13892] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]